Immunotherapy combo shows promise against tough esophageal cancer

NCT ID NCT02998268

Ongoing Disease control Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation can help people with a certain type of esophageal cancer. The trial involves 42 adults whose cancer has not spread far but is locally advanced. The main goal is to see if this combination improves the chance of being cancer-free one year after treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus esophageal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL ADENOCARCINOMA

Contacts and locations

Locations

Rhode Island Hospital

Providence, Rhode Island, 02903, United States
USC Keck School of Medicine, Norris Cancer Center

Los Angeles, California, 90033, United States
University of Michigan

Ann Arbor, Michigan, 48109-5848, United States
Weill Cornell Medicine

New York, New York, 10068, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.